Affimed N.V.
NASDAQ:AFMD
1.19 (USD) • At close December 20, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Affimed N.V. |
Symbool | AFMD |
Munteenheid | USD |
Prijs | 1.19 |
Beurswaarde | 18,120,725 |
Dividendpercentage | 0% |
52-weken bereik | 1.144 - 8.95 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Adi Hoess M.D., Ph.D. |
Website | https://www.affimed.com |
An error occurred while fetching data.
Over Affimed N.V.
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)